Orphazyme is in dialog with a number of potential suitors in search of rescue

Biotech company Orphazyme is in need of a lifeline, and its deputy chair, Bo Jesper Hansen, is in talks with five to ten potential buyers and investors as a part of current restructuring plans.
Bo Jesper Hansen, deputy chair of the board at Orphazyme | Photo: Kåre Viemose
Bo Jesper Hansen, deputy chair of the board at Orphazyme | Photo: Kåre Viemose
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

On Thursday, Orphazyme released its restructuring plan, stating that potential investors and buyers had already been identified and contacted.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading